​

Burning Cash Isn’t the Problem. Burning Alignment Is. Every biotech founder fears the day the cash runs out. You track the burn rate. You watch the runway shrink. You delay hires. You negotiate term sheets from a place of panic. But here’s what most founders miss. 👉 Cash isn’t your biggest problem. Misalignment is. Not the obvious kind either. We’re not talking about personality clashes or investor drama. 👉 We’re talking about the type of quiet misalignment that appears to

High-content screening (HCS) has become a cornerstone in GPCR and phenotypic drug discovery, enabling researchers to quantify cellular responses with spatial, temporal, and mechanistic depth. For GPCR-focused programs, the ability to visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages that extend far beyond traditional biochemical or radioligand assays. Yet, despite remarkable progress, HCS workflows rema

When David Hodson’s lab teamed up with chemist Johannes Broichhagen aka JB (then a young researcher newly arrived during a home DIY moment), the goal was bold and elegant: Create a photo-switchable ligand to remotely control GPCR signaling with light. This was the moment when photopharmacology felt like the future. The literature was buzzing. Labs were competing. The idea was simple — turn signaling on or off with a flash of light.

Enter a long-term collaboration with chemist Dr. Johannes Broichhagen - aka JB — which, amusingly, began when Hodson opened the door wearing cleaning gloves mid home renovation.

Clean data can still mislead if the underlying assumptions aren’t tested. Schild analysis is one of the few tools that tells you whether your “competitive antagonist” is actually behaving competitively. This week, we help you tighten your interpretations and strengthen your decisions at the bench and in discovery. Breakthroughs this week: McGPCR multimodal model; Endocrine Metabolic GPCRs 2026; Pfizer–Metsera acquisition.